Search | Clinical Trials Finder

Conditions: Lymphoma, Nonneoplastic Condition
Interventions: DNA analysis, RNA analysis, laboratory biomarker analysis; Genetic · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: HIV Infections
Interventions: Interleukin-2; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Osteopenia, Osteoporosis
Interventions: Zoledronate, Zoledronate placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 18 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 33
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 21 more

Conditions: HIV
Interventions: TMC125, Placebo; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 32
States / cities: Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 29 more

Conditions: HIV Infection
Interventions: Vitamin D3 50,000 IU, Vitamin D3 placebo; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more

Conditions: Health Care Quality, Access, and Evaluation, Delivery of Health Care, Immune System Diseases, HIV Infections
Interventions: Rates of HIV testing and receipt of results, Sexual risk reduction; HIV knowledge improvement; Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 251 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Pregnancy in Adolescence, HIV
Interventions: Making Proud Choices, Making Proud Choices AND Getting To Outcomes; Behavioral
Lead sponsor: RAND; Other
Eligibility: 10 Years to 14 Years
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 4
States / cities: Auburn, Alabama • Huntsville, Alabama • Montgomery, Alabama + 1 more

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: HIV Infections
Interventions: Enfuvirtide, Highly active antiretroviral treatment (HAART); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Cleveland, Ohio • Austin, Texas • Dallas, Texas

Conditions: HIV Infections, Adherence, Medication
Interventions: Tech2Check; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 25 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Jacksonville, Florida • Baltimore, Maryland

Conditions: HIV Negative, Adaptive Immunity, Innate Immunity
Interventions: VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alcohol Consumption
Interventions: Alcohol beverage, Placebo beverage; Other
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV-1-infection, HIV Disease Progression, Inflammation, HIV
Interventions: Venipuncture, Targeted physical medical exam, Urine pregnancy test, Anoscopy, Esophagogastroduodenoscopy (EGD); Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 7
States / cities: Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more

Conditions: HIV Infections
Interventions: HIV screening strategies; Other
Lead sponsor: Westat; Other
Eligibility: 14 Years to 24 Years
Enrollment: 84,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: HIV Infections, HIV
Interventions: IL-7; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV-1
Interventions: VRC-HIVMAB080-00-AB, VRC-HIVMAB075-00-AB; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • St Louis, Missouri + 3 more

Conditions: HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions: Capsaicin Dermal Patch; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 35
States / cities: Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more

Conditions: HIV, Alcohol Use, Medication Adherence
Interventions: Immediate PLUS intervention, Wait-list PLUS intervention; Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: CD4 Antigens, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: New Orleans, Louisiana • New York, New York

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 20 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 48
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 30 more

Conditions: HIV Infections, Adherence, Medication
Interventions: PrEP4T, LS4TM; Behavioral
Lead sponsor: Fenway Community Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Nevirapine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Beverly Hills, California • San Francisco, California • Denver, Colorado + 7 more

Search by objective public record fields.

Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy

Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2

Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

Improving HIV Screening With Nurse-Based Rapid Testing/Streamlined Counseling

Enhancing Quality Interventions Promoting Healthy Sexuality

Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections

A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience

Technology Based Community Health Nursing to Improve Combination Anti-Retroviral Therapy (cART) Adherence and Virologic Suppression in Youth Living With HIV

Immune Responses to Two Experimental HIV Vaccines in Healthy Adults

Effect of Acute Alcohol Intoxication on Neural Processes During Decisions to Engage in HIV Risk Behaviors

Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Screen2Prevent (S2P)

Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment

Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings

A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)

A "Pre-Enrollment" Protocol for HIV-Infected Adolescents

Transmasculine One-on-One and Group Empowerment for Targeted HIV Reduction

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors